05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
01:12 , Jun 16, 2018 |  BioCentury  |  Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and...
00:12 , May 5, 2018 |  BioCentury  |  Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Kazano regulatory update

Japan approved an NDA from Takeda for Inisync alogliptin/metformin to treat Type II diabetes. The fixed-dose combination of alogliptin and metformin is approved as Kazano in the U.S. and as Vipdomet in the EU for...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Finesse with Linzess

Thanks to a relatively flat expense line in 2Q16, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) almost doubled proceeds from its Linzess linaclotide deal with Allergan plc (NYSE:AGN). Going forward, the biotech expects to be able to deploy...
01:53 , Mar 3, 2016 |  BC Extra  |  Company News

Management tracks

Infectious disease company Spero Therapeutics LLC (Cambridge, Mass.) named Cristina Larkin chief commercial officer. She was assistant VP at Forest Laboratories Inc. , which Allergan plc (NYSE:AGN) acquired. Protein degradation company Arvinas LLC (New Haven,...
00:55 , Sep 18, 2015 |  BC Extra  |  Company News

Management tracks

Neurology play Marathon Pharmaceuticals LLC (Northbrook, Ill.) named Jordon Dubow CMO and VP of clinical and medical affairs. Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics...
07:00 , Sep 14, 2015 |  BioCentury  |  Finance

Gaining leverage

Carl Icahn wants to buy up convertible notes of Vivus Inc. (NASDAQ:VVUS), and if the debt holders agree to his terms the financier would gain a major bargaining chip with the obesity play. Vivus shareholders...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Allergan, Merck sales and marketing update

Allergan launched 2.5 mg Saphris asenapine black cherry-flavored sublingual tablets in the U.S. to treat manic or mixed episodes associated with bipolar I disorder in patients ages 10-17. Allergan already markets 5 and 10 mg...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Mylan sales and marketing update

Mylan launched 5 and 10 mg memantine tablets in the U.S. to treat moderate to severe dementia from Alzheimer’s disease (AD). Memantine is a generic of Namenda from Merz GmbH & Co. KGaA (Frankfurt, Germany)....